Cat. No. | Product name | CAS No. |
DC57073 |
VX-150
Featured
VX-150 (EOS-62073), a NaV1.8 blocker, is currently in a phase II clinical trial for the treatment of patients with acute pain. VX-150 significantly alleviates postoperative pain. |
1793080-72-4 |
DC60116 |
Pimethixene
Featured
Pimethixene or Calmixen is antihistamine and anticholinergic of the thioxanthene chemical class that is often used to treat hyperactivity, anxiety, sleep disorders, and allergy. |
314-03-4 |
DC60117 |
RS-25344 hydrochloride
Featured
RS-25344 HCl is a potent and selective phosphodiesterase (PDE) 4 inhibitor (IC50 values are 0.28, > 100, 160 and 330 nM at PDE4, PDE1, PDE2 and PDE3 respectively). It inhibits eosinophil chemotaxis and increases progressive motility of spermatozoa in vitro. |
152815-28-6 |
DC57076 |
GPR65 agonist (BTB09089)
Featured
GPR65 agonist (BTB09089) is a novel GPR65 agonist. |
245728-44-3 |
DC60118 |
Fezolinetant HCl
Featured
Fezolinetant, also known as ESN-364, is Neurokinin-3 (NK-3) receptor antagonist which has been optimized for use in women’s health, and is being developed for sex-hormone related disorders such as endometriosis, polycystic ovarian syndrome and uterine fibroids. |
929016-98-8 |
DC57080 |
XEN723
Featured
XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of Stearoyl-CoA Desaturase (SCD1) with IC50s of 45 and 524 nM in mouse and HepG2 cell, respectively. |
1072803-08-7 |
DC57081 |
FIDAS-3
Featured
FIDAS-3 is a stilbene derivative and is a potent Wnt inhibitor with an IC50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A). FIDAS-3 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-3 has anticancer activities. |
1266684-01-8 |
DC57083 |
Necrostatin-34
Featured
Necrostatin-34 (Nec-34), a RIPK1 kinase inhibitor, stabilizes RIPK1 kinase in an inactive conformation by occupying a distinct binding pocket in the kinase domain. |
375835-43-1 |
DC57085 |
TAK-653
Featured
TAK 653 (also known as NBI 1065845) is an oral small molecule, positive allosteric modulators of AMPA (AMPA-PAM) receptors |
1358751-06-0 |
DC57090 |
MIPS-521
Featured
MIPS521 is a positive allosteric modulator of the adenosine A1 receptor. |
1146188-19-3 |
DC60119 |
YQ128
Featured
YQ128 is a potent and selective second-generation NLRP3 (NOD-like receptor P3) inflammasome inhibitor with an IC50 of 0.30 ± 0.01 μM. Further studies from in vitro and in vivo models confirmed its selective inhibition on the NLRP3 inflammasome and its brain penetration. Furthermore, pharmacokinetic studies in rats at 20 mg/kg indicated extensive systemic clearance and tissue distribution, leading to a half-life of 6.6 h. |
2454246-18-3 |
DC60120 |
QQN05022(Dot1L-IN-4)
Featured
QQN05022, also known as Dot1L-IN-4 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor. This molecule was first reported in ACS Medicinal Chemistry Letters (2019), 10(12), 1655-1660. This product has no formal name at the moment. For the convenience of communication, a temporal code name was therefore proposed according to MedKoo Chemical Nomenclature. |
2565705-02-2 |
DC60121 |
NVP-BHG712 isomer
Featured
NVP-BHG712 isomer is a regioisomer of NVP-BHG712, which shows conserved non-bonded binding to EPHA2 and EPHB4. BHG-712, is a EphB4 kinase inhibitor and BCR-ABL inhibitor. NVP-BHG712 inhibits EphB4 kinase activity in the low nanomolar range in cellular assays showed high selectivity for targeting the EphB4 kinase when profiled against other kinases in biochemical as well as in cell based assays. |
2245892-85-5 |
DC60122 |
SC-10914
Featured
SC10914 is a highly potent PARP inhibitor (PARP1 IC50 = 7.87 nM) with potent anti-proliferative activity against human BRCA deficient tumor cells (MDA-MB-436, BRCA1 deficient, IC50 = 4.03 nM, Capan-1 BRCA2 deficient, IC50 = 11.66 nM) and PTEN deficient tumor cells (HGC-27,PTEN deficient, IC50 = 0.35 μM). SC10914 showed potent anti-tumor activity in BRCA1/2 mutant tumor models and better pharmacokinetics profile has the potential to be selected as the clinical candidate for the treatment of treatment of BRCA1/2 deficient cancers. |
76985-08-5 |
DC60123 |
N-desethyl Amodiaquine HCl
Featured
N-desethyl Amodiaquine is a primary metabolite of the antimalarial compound aminodiaquine, produced by the action of cytochrome P450 isoform 2C8. N-desethyl Amodiaquine is highly active against P. falciparum and can synergize with amodiaquine. |
79049-30-2 |
DC57082 |
MC-MMAE
Featured
Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Mc-MMAE is a drug-linker conjugate for ADC. |
863971-24-8 |
DC57088 |
SU0268
Featured
SU0268 is a potent and selective OGG1 inhibitor. DNA glycosylases involved in the first step of the DNA base excision repair pathway are promising targets in cancer therapy. There is evidence that reduction of their activities may enhance cell killing in malignant tumors. |
2210228-45-6 |
DC57110 |
MAT2A inhibitor-2
Featured
MAT2A inhibitor 2 is a methionine adenosyltransferase 2A (MAT2A) inhibitor. |
13299-99-5 |
DC60124 |
nor-NOHA HCl
Featured
nor-NOHA, also known as N-Hydroxy-nor-L-Arginine, is an Arginase inhibitor. nor-NOHA induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target. Nor-NOHA can induce cell apoptosis and inhibit the ability of invasion and migration of HepG2 cells by inhibiting Arg1, which is related with the increase of iNOS expression and the high concentration of NO. |
291758-32-2 |
DC46818 |
ACT-451840
Featured
ACT-451840 is an orally active, potent and low-toxicity compound, showing activity against sensitive and resistant plasmodium falciparum strains. ACT-451840 targets all asexual blood stages of the parasite, has a rapid onset of action. ACT-451840 behaves in a way similar to artemisinin derivatives, with very rapid onset of action and elimination of parasite. ACT-451840 can be used for the research of malarial. |
1984890-99-4 |
DC46833 |
Pulrodemstat
Featured
Pulrodemstat (CC-90011) is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC50 of 0.25 nM. Pulrodemstat is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. Pulrodemstat induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity. |
1821307-10-1 |
DC46834 |
Menin-MLL inhibitor 20,MRN73473
Featured
Menin-MLL inhibitor 20 is an irreversible menin-MLL interaction inhibitor with antitumor activities (WO2020142557A1, compound 6). |
2448173-47-3 |
DC46835 |
Ziftomenib
Featured
Ziftomenib is a menin-MLL interaction inhibitor with antitumor activities (WO2017161028A1, compound 151). |
2134675-36-6 |
DC46840 |
Mesdopetam
Featured
Mesdopetam (IRL790) is an orally active and low toxicity dopamine D3 receptor antagonist. Mesdopetam can be used for the research of Parkinson's disease (PD). |
1403894-72-3 |
DC46844 |
Emraclidine
Featured
Emraclidine is a muscarinic M4 receptor positive allosteric modulator (WO2018002760, compound 11). Emraclidine can be used for the research of neurological diseases. |
2170722-84-4 |
DC46850 |
SB 218795
Featured
SB 218795 is a potent and selective non-peptide NK3 receptor antagonist, with a Ki 13 nM for hNK3. SB 218795 shows about 90-fold and 7000-fold selectivity for hNK3 over hNK2 and hNK1, respectively. SB 218795 can inhibit NK3 receptor-mediated pupillary constriction of the rabbit. |
174635-53-1 |
DC46854 |
BMY-14802 hydrochloride
Featured
BMY-14802 hydrochloride (BMY-14802-1) is a selective and orally active sigma receptor antagonist with an IC50 of 112 nM. BMY-14802 hydrochloride is also a 5-HT1A and adrenergic α1 receptors agonist. BMY-14802 hydrochloride has antipsychotic effects. |
105565-55-7 |
DC46864 |
Sivopixant
Featured
Sivopixant (S-600918) is a potent and selective P2X3 receptor antagonist (P2X3 IC50=4.2 nM; P2X2/3 IC50=1100 nM). Sivopixant shows strong analgesic effect. |
2414285-40-6 |
DC46870 |
Enavogliflozin
Featured
Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor. |
1415472-28-4 |
DC46871 |
Vocacapsaicin
Featured
Vocacapsaicin (CA-008), a prodrug of Capsaicin, is a first-in-class non-opioid TRPV1 agonist. Vocacapsaicin can provide meaningful and long-lasting pain relief. |
1931116-86-7 |
DC46872 |
Evifacotrep
Featured
Evifacotrep, a short transient receptor potential channel 5 (TRPC5) antagonist (WO2020061162, compound 100), can be used for the research of neurological diseases. |
2413739-88-3 |
DC46877 |
Y134
Featured
Y134 is a selective and orally active oestrogen receptor (ER) modulator (SERM), exhibits potent antagonist activity at ERα and ERβ. Y134 shows 121.1-fold selectivity for ERα (Ki=0.09 nM) over ERβ (Ki=11.31 nM). |
849662-80-2 |
DC46880 |
Cedirogant
Featured
Cedirogant (ABBV-157) is an orally active RORγt inverse agonist. Cedirogant can be used for psoriasis research. |
2055496-11-0 |
DC46883 |
Tinlarebant
Featured
Tinlarebant (LBS-008) is an orally active non-retinoid RBP4 (retinol-binding protein 4) antagonist. Tinlarebant can be used for the research of the Stargardt disease. |
1821327-95-0 |
DC46887 |
CID1231538
Featured
CID1231538, a benzothiazole analogue, is a potent GPR35 antagonist (IC50=0.55 μM). GPR35 is a G protein-coupled receptor (GPCR). |
354126-20-8 |
DC46900 |
Utreloxastat
Featured
Utreloxastat is a compound used for the research of the disorders including α-synucleinopathies, tauopathies, Amyotrophic lateral sclerosis (ALS), traumatic brain injury, and ischemic-reperfusion related injuries (patent WO2020081879A2, example A1). |
1213269-96-5 |
DC46910 |
Sebetralstat
Featured
Sebetralstat is a plasma kallikrein inhibitor (WO2016083820). Sebetralstat can be used for the research of metabolic diseases. |
1933514-13-6 |
DC46916 |
2-bromo-Hexadecanoic acid
Featured
2-Bromohexadecanoic acid (2-BP, 2-bromopalmitate) is a nonmetabolisable analogue of palmitate and acts as a palmitoylation inhibitor. 2-Bromohexadecanoic acid can directly and irreversibly inhibit the palmitoyltransferase activity of all DHHC (Asp-His-His-Cys) proteins. |
18263-25-7 |
DC46917 |
[SER140]-PLP(139-151)
Featured
[SER140]-PLP(139-151) is a polypeptide fragment of the lipid protein of myelin. |
122018-58-0 |
DC46921 |
HPK1-IN-7
Featured
HPK1-IN-7 is a potent, orally active HPK1 (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC50=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1. |
2320462-65-3 |
DC46922 |
CC-99677
Featured
CC-99677 is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM). |
1887069-10-4 |
DC46943 |
Dalpiciclib
Featured
Dalpiciclib (SHR-6390) is a highly selective, orally bioavailable CDK4/6 inhibitor with comparable potencies against CDK4 (IC50=12.4 nM) and CDK6 (IC50=9.9 nM). Dalpiciclib exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated tumor-suppressor retinoblastoma protein (Rb) and inducing G1 cell cycle arrest. |
1637781-04-4 |
DC46946 |
PF-07220060
Featured
PF-07220060 is a potent CDK4/CDK6 inhibitor with a Ki of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively. |
2380321-51-5 |
DC46952 |
Iclepertin
Featured
Iclepertin (BI-425809) is a potent, selective and orally active glycine transporter 1 (GlyT1) inhibitor. Iclepertin is inactive against GlyT2. Iclepertin can be used for Alzheimer disease and schizophrenia research. |
1421936-85-7 |
DC46954 |
CVN03650(IL-17 modulator 4)
Featured
IL-17 modulator 4 is a prodrug of IL-17 modulator 1. IL-17 modulator 1 is an orally active, highly efficacious IL-17 modulator. |
2446803-65-0 |
DC46965 |
Tri-GalNAc-COOH
Featured
tri-GalNAc-COOH is an asialoglycoprotein receptor (ASGPR) ligand that can be used for LYsosome TArgeting Chimera (LYTAC) research. |
1953146-81-0 |
DC46967 |
Baxdrostat
Featured
Baxdrostat is a aldosterone synthase inhibitor. |
1428652-17-8 |
DC57120 |
PF07321332(nirmatrelvir)
Featured
PF07321332(nirmatrelvir) is a potent and orally active SARS-CoV 3C-like protease (3CLPRO) inhibitor . PF-07321332 targets to the SARS-CoV-2 virus and can be used for COVID-19 reseacrch. |
2628280-40-8 |
DC57880 |
MRTX1133(MRTX-1133)
Featured
MRTX 1133 is a potent and selective KRAS G12D inhibitor. MRTX1133 targets the KRAS G12D protein in both active and inactive states. In preclinical studies, MRTX1133 exhibited a long half-life, an ability to bind the KRAS G12D protein in both active and inactive states, and selective inhibition of KRAS G12D mutant cancer cells. |
2621928-55-8 |
DC57111 |
UNC6934
Featured
UNC6934 is a potent and selective drug-like chemical probe to interrogate the function of NSD2-PWWP1 with Kd of 91 nM.UNC6934 disrupts the NSD2-PWWP1 interaction with H3K36me2 nucleosomes in U2OS cells as measured by a NanoBret assay with an IC50 of 1.09 |
2561494-77-5 |
DC60125 |
JH-X-119-01
Featured
Jh-X-119-01 is a novel potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 irreversibly labels IRAK1 at C302. This compound exhibited cytotoxic activity at single digit micromolar concentrations in a panel of WM, DLBCL, and lymphoma cell lines expressing MYD88. Cotreatment of JH-X-119-01 with the BTK inhibitor ibrutinib resulted in synergistic killing effects in these systems. |
2227368-54-7 |
DC60126 |
KB-0742 HCl
Featured
KB-0742 is an orally bioavailable, selective CDK9 inhibitor with potent anti-tumor activity in CRPC models. |
2416873-83-9 |
DC60128 |
Benitrobenrazide
Featured
Benitrobenrazide is a novel selective hexokinase 2 (HK2) inhibitor, blocking cancer cells growth by targeting glycolysis. |
2454676-05-0 |
DC60130 |
ML303
Featured
ML303 is an antagonist of pyrazolopyridine influenza virus nonstructural protein 1 (NS1) (IC90 : 155 nM). |
1638211-04-7 |
DC60131 |
G244-LM
Featured
G244-LM is a potent and specific inhibitor of tankyrase 1/2 that inhibits Wnt signaling. |
1563007-08-8 |
DC60132 |
API-1(NSC 177223)
Featured
API-1 is a potent Akt inhibitor, which induces GSK3-dependent, β-TrCP- and FBXW7-mediated Mcl-1 degradation, resulting in induction of apoptosis . API-1 rapidly and potently reduced the levels of Mcl-1 primarily in API-1-senstive lung cancer cell lines. Ectopic expression of Mcl-1 protected cells from induction of apoptosis by API-1. |
36707-00-3 |
DC60133 |
SAR405 R enantiomer
Featured
SAR405 R enantiomer is the less active enantiomer of SAR405. SAR405 is an inhibitor of PIK3C3/Vps34. |
1946010-79-2 |
DC60134 |
Soporidine
Featured
Soporidine is a strigolactone (SL) antagonist and inhibitor of germination in their biological assays. It binds AtHTL and specifically interferes with SL signaling. |
1060376-43-3 |
DC60135 |
Sortin-3
Featured
Sortin3 is a sorting inhibitor, blocking Vps16 function, one protein in the class C tethering complex, and increasing aflatoxin synthesis and export. |
|
DC60136 | 2-(Aminosulfonyl)benzoic acid Featured | 632-24-6 |
DC60137 | Imidacloprid Impurity 1 Featured | 105828-41-9 |
DC60138 | Imidacloprid-urea Featured | 120868-66-8 |
DC60139 | 2-(nitroimino)imidazolidine Featured | 54565-96-3 |
DC60140 |
Pyrimorph
Featured
Pyrimorph is a fungicide with high activity against the plant pathogen Phytophthora capsici. Pyrimorph inhibited different stages in the life cycle of P. capsici including mycelial growth, sporangium production, zoospore release, and cystospore germination with EC(50) values of 1.84, 0.17, 4.92, and 0.09 microg mL(-1), respectively. |
868390-90-3 |
DC60141 | MH-26774 Featured | |
DC60142 |
DL5H3
Featured
DL5H3 is a biochemical. |
90263-34-6 |
DC60143 |
MT 63-78
Featured
MT 63-78 is a specific and effective direct AMPK activator (EC50: 25 μM). MT 63-78 blocks prostate cancer growth by inhibiting the lipogenesis and mTORC1 pathways. MT 63-78 has antitumor effects. MT 63–78 also causes cell mitotic arrest and apoptosis. |
1179347-65-9 |
DC60144 |
MCULE-3408819416
Featured
MCULE-3408819416|DC Chemicals |
|
DC60145 |
GW805758X
Featured
GW805758X is a potent inhibitor of CDK-4 which demonstrates enzyme selectivity against VEGFR-2 and GSK3β. |
|
DC60146 |
BTA-EG4 hydrate
Featured
BTA-EG4, acts as an amyloid-binding small molecule that promotes dendritic spine density and cognitive function in wild-type mice. |
921193-28-4 |
DC60148 |
Coumarin-TMP-Halo
Featured
Coumarin-TMP-Halo is a specific fluorescent protein labeling agent. |
2137894-99-4 |
DC60149 |
1-Boc-1,8-diaminooctane
Featured
tert-butyl (8-aminooctyl)carbamate can be used as a PROTAC linker in the synthesis of PROTACs. tert-butyl (8-aminooctyl)carbamate is an alkane chain with terminal amine and Boc-protected amino groups. Amine group is reactive with carboxylic acids, activated NHS esters, carbonyls (ketone, aldehyde) etc. The Boc group can be deprotected under mild acidic conditions to form the free amine. |
88829-82-7 |
DC60150 | S-[2-(4-Pyridyl)ethyl]-L-cysteine Featured | 28809-04-3 |
DC60151 | TET-IN-C35 Featured | |
DC60152 |
SHIN 2, SHIN-2
Featured
SHIN-2 is a novel SHMT inhibitor, increasing survival in NOTCH1-driven mouse primary T-ALL in vivo |
2204289-53-0 |
DC60153 |
2-(2-bromophenyl)-5-chloro-4H-3,1-benzoxazin-4-one
Featured
2-(2-bromophenyl)-5-chloro-4H-3,1-benzoxazin-4-one is an human neutrophil elastase inhibitor. |
1234707-32-4 |
DC60154 |
Miclxin
Featured
Miclxin, a Novel MIC60 Inhibitor, Induces Apoptosis via Mitochondrial Stress in β-Catenin Mutant Tumor Cells |
2494198-61-5 |
DC46982 |
Setmelanotide acetate
Featured
Setmelanotide (RM-493, BIM-22493, CAM 4072) is a cyclic peptide full agonist of melanocortin-4 receptor (MC4R) with an EC50 of 0.27 nM and a Ki of 2.1 nM. |
1504602-49-6 |
DC46984 |
Lonodelestat
Featured
Lonodelestat (POL6014) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE). |
906547-89-5 |
DC46999 |
Sec61-IN-1
Featured
Sec61-IN-1 is a potent sec61 inhibitor (Patent WO2020176863A1, compound A317). |
2484865-42-9 |
DC47003 |
Bevurogant
Featured
Bevurogant is a retinoid-related orphan receptor-gamma t (RORγt) antagonist. Bevurogant can be used for the research of chronic inflammatory diseases. |
1817773-66-2 |
DC47009 |
Zabedosertib
Featured
Zabedosertib (BAY 1834845) is a IRAK4 inhibitor with immunomodulatory potential. IRAK4 is a protein kinase involved in signaling innate immune responses from Toll-like receptors. |
1931994-81-8 |
DC47017 |
Vibozilimod
Featured
Vibozilimod (example 33) is a S1p1 receptor agonist (extracted from patent WO2012140020A1). |
1403232-33-6 |
DC47029 |
Selnoflast
Featured
Selnoflast (example 6) is a NLRP3 inhibitor (extracted from patent WO2019008025). |
2260969-36-4 |
DC47038 |
Fosifidancitinib
Featured
Fosifidancitinib is a potent and selective inhibitor of JAK kinases 1/3. Fociatinib is used in studies of allergies, asthma and autoimmune diseases. |
1237168-58-9 |
DC47048 |
Rebamipide mofetil
Featured
Rebamipide mofetil is an orally active prodrug of Rebamipide (OPC12759). Rebamipide is a mucoprotective agent. Rebamipide induces COX-2 expression, increases PGE2 levels, and enhances gastric mucosal defense in a COX-2-dependent manner. |
1527495-76-6 |
DC47051 |
Temgicoluril
Featured
Tetramethylglycerol (Tetramethylglycoluril) is a small molecule that acts on GABA Receptor, with anti-anxiety activity. |
10095-06-4 |
DC47053 |
Tigulixostat
Featured
Tigulixostat is a novel (indolyl)heteroarylcarboxylate derivatives effective as non-purine selective xanthine oxidase inhibitor, which lowers the production of uric acid. |
1287766-55-5 |
DC47057 |
Vazegepant
Featured
Vazegepant is the first intranasal CGRP receptor antagonist for the study the acute research of migraine. |
1337918-83-8 |
DC47060 |
Ansofaxine
Featured
Ansofaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) used for the research of depression. |
916918-80-4 |
DC47062 |
Bersacapavir
Featured
Bersacapavir is a novel Hepatitis B Virus capsid assembly modulator. |
1638266-40-6 |
DC47066 |
Ifidancitinib
Featured
Ifidancitinib is a potent and selective inhibitor of JAK kinases 1/3. Ifidancitinib can be used in studies of allergies, asthma and autoimmune diseases. |
1236667-40-5 |
DC47069 |
Ninerafaxstat
Featured
Ninerafaxstat hifts cellular metabolism from fatty acid oxidation to glucose oxidation.Ninerafaxstat decreases fatty acid oxidation and improve overall mitochondrial respiration.Ninerafaxstat inhibit the growth and proliferation of cancer cells. |
2254741-41-6 |
DC47080 |
Velufenacin
Featured
Velufenacin is a muscarinic receptor antagonist. |
1648737-78-3 |
DC47084 |
Abrucomstat
Featured
Abrucomstat (3-Nitroxypropanol) acts as an enzyme inhibitor to decrease ruminal methanogenesis. |
100502-66-7 |
DC47090 |
Etavopivat
Featured
Etavopivat is a potent, selective, orally bioavailable red blood cell (RBC) pyruvate kinase (PKR) activator. Etavopivat has potent antisickling effects. |
2245053-57-8 |
DC47093 |
Fosciclopirox
Featured
Fosciclopirox suppresses growth of urothelial cancer by targeting the γ-secretase complex. Fosciclopirox selectively delivers the active metabolite, Ciclopirox (CPX), to the entire urinary tract. Ciclopirox has anticancer activity in a number of solid and hematologic malignancies. |
1380539-06-9 |
DC47094 |
MK-3984
Featured
MK-3984 is a selective androgen receptor modulator (SARM). MK-3984 can be used for the research of muscle wasting associated with cancer. |
871325-55-2 |
DC47113 |
DS44960156
Featured
DS44960156 is a selective Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) inhibitor, with IC50 values of 1.6 μM and >30 μM for MTHFD2 and MTHFD1, respectively. |
2361327-08-2 |
DC47117 |
MRTX-1719
Featured
MRTX-1719 is a potent first-in-class selective inhibitor of the PRMT5/MTA complex, with an IC50 of less than 10 nM in PRMT5/MTA MTAPDEL SDMA cells. |
2630904-45-7 |
DC47131 |
ATR inhibitor 4
Featured
ATR inhibitor 4 (compound 121) is a potent ATR inhibitor. ATR inhibitor 4 has antitumor activity. |
2417489-10-0 |
DC47132 |
JAK1-IN-8
Featured
JAK1-IN-8, a potent JAK1 inhibitor (IC50<500 nM), compound 28, extracted from patent WO2016119700A1. |
1973485-18-5 |
DC47146 |
Bicyclopyrone
Featured
Bicyclopyrone is an inhibitor of 4-hydroxyphenylpyruvate dioxygenase (Hpd). |
352010-68-5 |
DC47165 |
CDC25B-IN-2
Featured
CDC25B-IN-2 is a potent cdc25B inhibitor. |
134271-74-2 |
DC47171 |
ARD-2585
Featured
ARD-2585 is an exceptionally potent and orally active PROTAC degrader of androgen receptor. |
2757422-79-8 |
DC47176 |
GW 590735
Featured
GW 590735 is a potent and selective PPARα agonist. GW 590735 showsEC50=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia. |
343321-96-0 |
DC47191 |
Sovilnesib(AMG-650)
Featured
Sovilnesib(AMG650) is a kinesin-like protein KIF18A inhibitor (WO2020132648). Sovilnesib can be used for the research of cancer. |
2410796-79-9 |
DC47194 |
IL-4-inhibitor-1
Featured
IL-4-inhibitor-1 (compound 52) is an IL-4 inhibitor, with an EC50 of 1.81 µM. |
1332184-63-0 |
DC47195 |
Inaxaplin
Featured
Inaxaplin is an apolipoprotein L1 (APOL1) function inhibitor (WO2020131807, compound 2). Inaxaplin can be used for the research of kidney disease. |
2446816-88-0 |
DC47210 |
JDQ-443
Featured
JDQ443 (example 1a) is a covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). |
2653994-08-0 |
DC47216 |
Thalidomide-5,6-F
Featured
Thalidomide-5,6-F is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-5,6-F can be connected to the ligand for protein by a linker to form PROTACs. |
1496997-41-1 |
DC47230 |
Emivirine
Featured
Emivirine is a non-nucleoside reverse transcriptase inhibitors (NNRTIs) that displays potent and selective anti-human immunodeficiency virus type 1 (HIV-1) activity. |
149950-60-7 |
DC47231 |
Dup-721
Featured
DuP-721 is a broad spectrum and orally active antibacterial agent against a variety of clinically susceptible and resistant bacteria, especially M. tuberculosis. |
104421-21-8 |
DC47237 |
PD 102807
Featured
PD 102807 is a M4 muscarinic receptor antagonist with an IC50 of 90.7 nM. PD 102807 inhibits M1, M2, M3, M5 muscarinic receptor with IC50s of 6558.7, 3440.7, 950.0, and 7411.7 nM, respectively. Antidyskinetic effect. |
23062-91-1 |
DC47256 |
TJ-M2010-5
Featured
TJ-M2010-5 is a MyD88 inhibitor that binds to the TIR domain of MyD88 to interfere with its homodimerization, and the TLR/MyD88 signal pathway. TJ-M2010-5 can be used for the research of myocardial ischemia/reperfusion injury (MIRI). |
1357471-57-8 |
DC47259 |
Inarigivir ammonium
Featured
Inarigivir (ORI-9020) ammonium is a dinucleotide antiviral drug which can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) act as an RIG-I agonist to activate cellular innate immune responses. |
2172788-92-8 |
DC47260 |
Zunsemetinib
Featured
Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases. |
1640282-42-3 |
DC47269 |
Samuraciclib
Featured
Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib has anti-tumor effects. |
1805833-75-3 |
DC47270 |
(S)-Amisulpride
Featured
(S)-Amisulpride (Esamisulpride) is a potent dopamine D2/D3 receptor antagonist. (S)-Amisulpride is an antagonist at the 5-HT7 receptor with a KI of 900 nM. (S)-Amisulpride has antipsychotic and antidepressant effects. |
71675-92-8 |
A273 |
Datopotamab deruxtecan
Featured
Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan has a potent antitumor activity. |
2238831-60-0 |
DC47280 |
Nusinersen
Featured
Nusinersen is an antisense oligonucleotide drug that modifies pre–messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein. |
1258984-36-9 |
DC47285 |
Tofersen
Featured
Tofersen (BIIB067) is an antisense oligonucleotide that mediates RNase H-dependent degradation of superoxide dismutase 1 (SOD1) mRNA to reduce the synthesis of SOD1 protein. Tofersen can be used for the research of amyotrophic lateral sclerosis (ALS). |
2088232-70-4 |
DC47287 |
Tivanisiran
Featured
Tivanisiran (SYL1001) is a siRNA used for the study of dry eye disease. Tivanisiran was designed to silence transient receptor potential vanilloid 1 (TRPV1). |
1848224-71-4 |
DC47290 |
Remlarsen
Featured
Remlarsen (MRG-201), a miR-29b mimic, acts a miR-29b agonist. Remlarsen has the potential for preventiong formation of a fibrotic scar or cutaneous fibrosis. |
1848266-71-6 |
DC47291 |
Miravirsen
Featured
Miravirsen (SPC-3649), a β-d-oxy-locked nucleic acid-modified phosphorothioate antisense oligonucleotide, inhibit the biogenesis of miR-122. Miravirsen (SPC-3649) is used in the study for HCV infections. |
1072874-90-8 |
DC47292 |
Inclisiran
Featured
Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research. |
1639324-58-5 |
DC47306 |
ARO-AAT
Featured
ARO-AAT is a second-generation RNAi drug. ARO-AAT consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade AAT mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes. |
2175009-08-0 |
DC47308 |
Lumasiran
Featured
Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1). |
1834610-13-7 |
DC47310 |
Rovanersen
Featured
Rovanersen (WVE-120101) is an antisense oligonucleotide that can be used for huntington’s disease research. |
2072901-32-5 |
DC47315 |
ML-SI3
Featured
ML-SI3 is a potent TRPML channel inhibitor with IC50s of 4.7 µM and 1.7 µM for TRPML1 and TRPML2, respectively. |
891016-02-7 |
DC47316 |
LOX-IN-3 Dihydrochloride
Featured
LOX-IN-3 Dihydrochloride is an orally active and selective lysyl oxidase (LOX) inhibitor. |
2409964-23-2 |
DC47318 |
7,12-Dimethylbenz[a]anthracene (DMBA)
Featured
7,12-Dimethylbenz[a]anthracene (DMBA) is an immunosuppressor as well as a potent organ-specific carcinogen. |
57-97-6 |
DC60155 |
Lu AF27139
Featured
Lu AF27139 is a novel rodent-active and CNS-penetrant P2X7 receptor antagonist. Lu AF27139 is highly selective and potent against rat, mouse, and human forms of the receptors. The rat pharmacokinetic profile is favorable with high oral bioavailability, modest clearance (0.79 L/(h kg)), and good CNS permeability. Importantly, Lu AF27139 was without effect in standard in vitro and in vivo toxicity studies. Lu AF27139 is a valuable tool for probing the role of the P2X7 receptor in rodent models of CNS diseases. |
2097117-06-9 |
DC60156 |
Rasarfin
Featured
Rasarfin is a novel dual Ras and ARF6 inhibitor. Rasarfin blocks agonist-mediated internalization of AT1R and other GPCRs. Rasarfin also potently inhibits agonist-induced ERK1/2 signaling by GPCRs, and MAPK and Akt signaling by EGFR, as well as prevents cancer cell proliferation. In silico modeling and in vitro studies reveal a unique binding modality of Rasarfin within the SOS-binding domain of Ras. Rasarfin is a novel dual Ras and ARF6 inhibitor. Rasarfin blocks agonist-mediated internalization of AT1R and other GPCRs. Rasarfin also potently inhibits agonist-induced ERK1/2 signaling by GPCRs, and MAPK and Akt signaling by EGFR, as well as prevents cancer cell proliferation. In silico modeling and in vitro studies reveal a unique binding modality of Rasarfin within the SOS-binding domain of Ras. |
674359-73-0 |
DC60157 |
KYN101
Featured
KYN-101 is a novel potent and selective inhibitor of aryl hydrocarbon receptor (AHR) (IC50 of 22 nM in the human HepG2 DRE-luciferase reporter assay and 23 nM in the murine Hepa1 Cyp-luc assay). |
|
DC60158 |
K-975
Featured
K-975 is a first-in-class TEAD inhibitor, directly inhibiting YAP/TAZ-TEAD protein-protein interaction and showing a potent anti-tumor effect in malignant pleural mesothelioma. K-975 was covalently bound to an internal cysteine residue located in the palm |
2563855-03-6 |
DC60159 |
Azo-Resveratrol
Featured
Azo-Resveratrol is an analog of Resveratrol used as a potent tyrosinase inhibitor. |
1393556-48-3 |
DC60160 |
Homo-VK-II-36
Featured
Homo-VK-II-36 is a carvedilol analogue. It acts by inhibiting store-overload-induced calcium release (SOICR) through the RyR2 channel. |
|
DC60161 |
NSC2805
Featured
NSC-2805 is a WWP2 ubiquitin ligase inhibitor. |
4371-34-0 |
DC60162 |
GPR52-IN-43(CAY10786)
Featured
GPR52-IN-43(CAY10786) is a novel GPR52 antagonist, reducing mHTT levels by targeting GPR52 and promoting survival of mouse primary striatal neurons, and also reducing HD-related phenotypes in HdhQ140. |
1239987-91-7 |
DC60163 | FPPS-IN-11 Featured | 1250273-31-4 |
DC60165 | DoPAT Featured | 558484-21-2 |
DC60166 | Benzenecarbodithioicacid, phenylmethyl ester Featured | 27249-90-7 |
DC60167 | Benzene, 1-[(1R)-1-(bromomethoxy)ethyl]-3,5-bis(trifluoromethyl)- Featured | 530441-95-3 |
DC60168 | ethyl 2-ethoxycarbothioylsulfanylpropanoate Featured | 73232-07-2 |
DC60169 | 2,3,5,6-tetrahydropentalen-1(4H)-one Featured | 10515-92-1 |
DC60170 | Propanoic acid, 3-[[[(phenylmethyl)thio]thioxomethyl]thio]- Featured | 497931-76-7 |
DC60171 |
ML353 (VU0478006)
Featured
ML353 (VU0478006) is a ovel Silent Allosteric Modulator (SAM) of the Metabotropic Glutamate Receptor 5. |
|
DC60172 | SY292470 Featured | 1360900-71-5 |
DC60173 |
BR-103354
Featured
BR103354 is a novel fibroblast activation protein (FAP) inhibitor with anti-diabetic and anti-steatotic effects. |
2505339-87-5 |
DC60174 |
CAY10526
Featured
CAY10526 is a selective inhibitor of mPGES-1. It also acts as an inhibitor of the NF-κB signaling pathway. |
938069-71-7 |
DC60175 | VK-28 Featured | 312611-92-0 |
DC58000 |
4'-fluorouridine (4'-FlU, EIDD-2749)
Featured
4'-fluorouridine (4'-FlU, EIDD-2749) is a ribonucleoside analog that inhibits respiratory syncytial virus (RSV), related RNA viruses, and SARS-CoV-2 with high selectivity index (EC50/CC50 of ≥1877) in cells and human airway epithelia organoids. 4'-FlU induces a delayed stalling of RSV and SARS-CoV-2 RdRP (RNA-dependent RNA polymerase). |
1613589-24-4 |
DC60176 |
M1001
Featured
M1001 is a novel allosteric agonist of hypoxia-inducible factor-2α subunit (hif-2α), significantly displacing pocket residue y281 |
874590-32-6 |
DC60177 |
Heparan N-sulfate
Featured
Heparan Sulfate is a complex and linear polysaccharide, exists as part of glycoproteins named heparan sulfate proteoglycans, which are expressed abundantly on the cell surface and in the extracellular matrix. |
9050-30-0 |
DC60178 | Abatacept Featured | 332348-12-6 |
DC60179 |
Tuspetinib(HM43239)
Featured
HM43239 is an orally active small molecule inhibitor of FLT3 that selectively inhibits not only FLT3 wild type, ITD mutants or TKD mutations, but also FLT3 ITD/TKD double mutations. HM43239 directly inhibits the kinase activity of FLT3 as a reversible Type I inhibitor and effectively modulates downstream p-STAT5 and p-ERK. HM43239 also demonstrated inhibition of SYK, JAK1/2 and TAK1, known to be involved in tumor cell proliferation and/or differentiation HM43239 monotherapy induced dose-dependent regression of tumor growth in FLT3 wild-type and FLT3 mutated leukemia cancer cell line. |
2294874-49-8 |
DC60180 |
BUN79398
Featured
BUN79398, also known as MRGPRX1 agonist 1, is a potent MRGPRX1 agonist (Mas-related G-protein-coupled receptor X1) (EC50 of 50 nM). BUN79398 is not only devoid of positively charged amidinium group but also with superior selectivity over opioid receptors. |
2377379-39-8 |
DC60181 |
dCBP-1
Featured
dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP based on Cereblon ligand. dCBP-1 is exceptionally potent at killing multiple myeloma cells and can abolish the enhancer that drives MYC oncogene expression. As an efficient degrader of this unique class of acetyltransferases, dCBP-1 is a useful tool alongside domain inhibitors for dissecting the mechanism by which these factors coordinate enhancer activity in normal and diseased cells. |
2484739-25-3 |
DC58005 |
Z-FF-FMK
Featured
Z-FF-FMK is a cell-permeant and irreversible inhibitor of cathepsin B and cathepsin L. |
105608-85-3 |
DC58006 |
Z-ASTD-FMK
Featured
Z-ASTD-FMK is a cell-permeant and irreversible inhibitor of endothelial monocyte-activated polypeptide II (EMAP II). |
|
DC58007 |
GSK3685032
Featured
GSK-3685032(GSK 3685032) is a first-in-class, potent, non-nucleoside, reversible, selective inhibitor of DNMT1 with IC50 of 0.036 μM. GSK3685032 induces robust loss of DNA methylation, transcriptional activation and cancer cell growth inhibition in vitro. |
2170137-61-6 |
DC58011 |
SKA-31
Featured
SKA-31 (Naphtho[1,2-d]thiazol-2-ylamine) is a potent activator of potassium channel with EC50 of 260 nM, 1.9 μM, 2.9 μM, and 2.9 μM for KCa3.1, KCa2.2, KCa2.1 and KCa2.3, respectively. |
40172-65-4 |
DC60182 |
Y 39983HCl
Featured
Y-39983, also known as Y-33075, is a potent and selective inhibitor of ROCK family with IC50 value of 3.6nM for ROCK. Y-39983 attenuates experimental autoimmune encephalomyelitis via inhibition of demyelination. Y-39983 downregulates RhoA/Rho-associated kinase expression during its promotion of axonal regeneration. Y-39983, promotes regeneration of crushed axons of retinal ganglion cells into the optic nerve of adult cats. |
471843-75-1 |
DC60183 |
GR-103545 fumarate
Featured
GR-103545 is a reference and non-radio labeled agent. The radio-labeled 11C-GR103545 is a promising PET radiotracer for imaging the κ-OR. |
126766-43-6 |
DC58030 |
R-Avanafil
Featured
Avanafil Impurity 8 |
1638497-26-3 |
DC58033 |
Nox inhibitor 1
Featured
Novel Nox inhibitor,N2-(3,4-Dimethylphenyl)-6-((4-(p-tolyl)piperazin-1- yl)methyl)-1,3,5-triazine-2,4-diamine |
|
DC47320 |
FRM-024
Featured
FRM-024 is a potent CNS-penetrant gamma secretase modulator for familial Alzheimer’s disease. |
2085780-87-4 |
DC47321 |
Endovion (NS 3728)
Featured
Endovion (NS 3728, SCO-101) is an potent anion channel inhibitor that blocks the Volume Regulated Anion Channels (VRAC). |
265646-85-3 |
DC47351 |
ASP2453
Featured
ASP2453 is a potent, selective and covalent KRAS G12C inhibitor. ASP2453 inhibits the Son of Sevenless (SOS)-mediated interaction between KRAS G12C and Raf with an IC50 value of 40 nM. |
2241719-73-1 |
DC47361 |
PZ703b
Featured
PZ703b is highly potent in killing BCL-XL dependent, BCL-2 dependent, and BCL-XL/BCL-2 dual-dependent cells in an E3 ligase (VHL)-dependent fashion. |
2471970-56-4 |
DC47376 |
Rimtuzalcap
Featured
Rimtuzalcap (CAD-1883) is a first-in-class selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels). Rimtuzalcap can be used for the research of movement disorders including essential tremor (ET) and spinocerebellar ataxia (SCA). |
2167246-24-2 |
DC47381 |
MOMIPP
Featured
MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP penetrates the blood-brain barrier (BBB). |
1363421-46-8 |
DC47383 |
GSK251
Featured
GSK251 is a highly potent, highly selective, orally bioavailable inhibitor of PI3Kδ with a novel binding mode. |
2125968-05-8 |
DC47388 |
PROTAC SHP2 degrader-1
Featured
PROTAC SHP2 degrader-1 is a potent and effective SHP2 degrader. PROTAC SHP2 degrader-1 induces SHP2 degradation requires binding to VHL-1 and SHP2 proteins and is also neddylation- and proteasome-dependent. |
2458219-65-1 |
DC47398 |
MMV666810
Featured
MMV666810, a 2-aminopyrazine similar to MMV390048, is potent against asexual parasites at 5.94 nM, but against gametocytes, it has a 3.3-fold selectivity to late-stage gametocytes compared to earlier stages (early-stage gametocyte: IC50 603 ± 88 nM; late-stage gametocyte: IC50 179 ± 8 nM). |
1450666-97-3 |
DC47399 |
MMV674850
Featured
MMV674850 is potent against asexual stage parasites at 2.7 and 4.5 nM and preferentially targets early-stage gametocytes (early-stage gametocyte: IC50 4.5 ± 3.6 nM; late-stage gametocyte: IC50 28.7 ± 0.2 nM). |
1820874-51-8 |
DC47420 |
(S)-ErSO
Featured
(S)-ErSO is the dextrorotatory enantiomer of ErSO. (S)-ErSO is inactive in MCF-7 cells (from patent WO2020009958A1, compound (s)-105). |
2407860-34-6 |
DC47427 |
MK-4688
Featured
MK-4688 is an efficient inhibitor of the HDM2-p53 protein-protein interaction. |
1616428-79-5 |
DC47434 |
DNDI-6148
Featured
DNDI-6148 acts principally through the inhibition of Leishmania cleavage and polyadenylation specificity factor (CPSF3) endonuclease for the treatment of visceral leishmaniasis (VL). |
2243909-59-1 |
DC47467 |
UZH2
Featured
UZH2 is a potent and selective METTL3 inhibitor with an IC50 value of 5 nM. |
2756566-45-5 |
DC47470 |
SBP-3264
Featured
SBP-3264 is a valuable chemical probe for understanding the roles of STK3 and STK4 in acute myeloid leukemia (AML). |
2869148-13-8 |
DC47483 |
RH-EDA
Featured
RH-EDA is a rhodamine-based turn-on fluorescent probe for detecting hydroxyl radicals in living systems. |
|
DC47507 |
BAY-091
Featured
BAY-091 is a novel potent and highly selective inhibitor of the kinase PIP4K2A. |
2922280-34-8 |
DC47522 |
BI-6015
Featured
BI-6015 is a hepatocyte nuclear factor 4α (HNF4α) antagonist that can inhibit the expression of known HNF4α target genes. BI6015 represses insulin promoter activity through HNF4α antagonism. BI-6015 can be used for the research of cancer and diabetes. |
93987-29-2 |
DC47557 |
Aficamten(CK274)
Featured
Aficamten (CK-274) is a novel cardiac myosin inhibitor with an IC50 of 1.4 μM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM). |
2364554-48-1 |
DC47561 |
MHY-1685
Featured
MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration. |
27406-31-1 |
DC47562 |
VB124
Featured
VB-124 is a potent and selective MCT4 inhibitor. VB124 might redirect glycolytic carbon flux into mitochondrial pyruvate oxidation. VB 124 bolcks lactate import (IC50=8.6nM), and export (IC50=19nM) in MDA-MB-231 cells that are engineers to express MCT4 as the only major plasma membrane lactate transporter. |
2230186-18-0 |
DC47581 |
BMS-986278
Featured
BMS-986278 is a potent lysophosphatidic acid receptor 1 (LPA1) antagonist, with a human LPA1 Kb of 6.9 nM. |
2170126-74-4 |
DC47591 |
JAK-IN-14
Featured
JAK-IN-14 is a potent and selective JAK1 inhibitor, with an IC50 of <5 μM. JAK-IN-14 is >8-fold more selective for JAK1 than JAK2 and JAK3 (Patent WO2016119700A1, compound 16). |
1973485-06-1 |
DC47604 |
GPS491
Featured
GPS491 (EC50 = 0.47 μM) suppresses expression of the HIV-1 structural protein Gag and alters HIV-1 RNA accumulation, decreasing the abundance of RNAs encoding the structural proteins while increasing levels of viral RNAs encoding the regulatory proteins. |
2655502-29-5 |
DC47608 |
EZH2-IN-2
Featured
EZH2-IN-2 is a EZH2 inhibitor extracted from patent WO2018133795A1, Compound Example 69, with an IC50 of 64 nM. EZH2-IN-2 can be used for the research of cancer or precancerous condition related to EZH2 activity. |
2238821-31-1 |
DC47614 |
EEDi-5273
Featured
EEDi-5273 is an exceptionally potent and orally efficacious embryonic ectoderm development (EED) inhibitor with IC50 of 0.2 nM and inhibits the KARPAS422 cell growth with IC50 of 1.2 nM. EEDi-5273 demonstrates an excellent PK and ADME profile, and its oral administration leads to complete and persistent tumor regression in the KARPAS422 xenograft model with no signs of toxicity. |
2585648-55-9 |
DC47616 |
EPZ-719
Featured
EPZ-719 is a novel and potent SETD2 inhibitor ( IC50 = 0.005 μM) with a high selectivity over other histone methyltransferases. |
2697176-16-0 |
DC47621 |
Seclidemstat mesylate
Featured
Seclidemstat (SP-2577) mesylate is a potent noncompetitive and reversible KDM1A (LSD1) inhibitor (Ki=31 nM, IC50=13 nM). Seclidemstat mesylate promotes antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, as well as inhibit virus production, viral DNA replication, and late gene expression. Seclidemstat mesylate can be used for the research of Ewing Sarcoma. |
2044953-70-8 |
DC47622 |
Cyclizine
Featured
Cyclizine is a piperazine first-generation antagonist of histamine 1 receptor. |
82-92-8 |
DC47635 |
GLP-1R modulator L7-028
Featured
GLP-1R modulator L7-028 is an allosteric modulator enhancing GLP-1 binding to GLP-1R via a transmembrane site (EC50 11.01 ± 2.73 μM). |
2648317-95-5 |
DC47678 |
M435-1279
Featured
M435-1279 is a UBE2T inhibitor. M435-1279 acts inhibit the Wnt/β-catenin signaling pathway hyperactivation through blocking UBE2T-mediated degradation of RACK1. |
1359431-16-5 |
DC47683 |
Mesdopetam hemitartrate
Featured
Mesdopetam (IRL790) hemitartrate is a dopamine D3 receptor antagonist (Ki=90 nM; IC50=9.8 μM for human recombinant D3 receptor) with psychomotor stabilizing properties. Mesdopetam hemitartrate is used for the research of motor and psychiatric complications in Parkinson disease. |
2562346-14-7 |
DC47703 |
BPR1R024
Featured
BPR1R024 is an orally active and selective CSF1R inhibitor with IC50 of 0.53 nM. BPR1R024 specifically inhibits protumor M2-like macrophage survival with a minimal effect on antitumor M1-like macrophage growth. |
2503015-75-4 |